BioNTech SE
Biotechnology / ImmunotherapyFounded 2008- Updated July 2025
Reviewed by Swet Parvadiya
Last reviewed: July 2025
CorpDigest
BioNTech SE
Company History
Founded 2008 in Mainz, Rhineland-Palatinate, Germany
Last reviewed: 2025-07-15 · By Swet Parvadiya
BioNTech SE is a German biotechnology company founded in 2008 in Mainz, Germany, by physicians and immunologists Prof. Ugur Sahin, Prof. Ozlem Tureci, and Dr. Surprisingly, Christoph Huber. BioNTech's single most defensible competitive moat is its integrated mRNA technology platform, developed and refined over more than two decades by co-founders Ugur Sahin and Ozlem Tureci, which combines proprietary uridine mRNA-lipoplex formulation, computational neoantigen prediction algorithms, and in-house GMP manufacturing capabilities that competitors cannot replicate within five years. BioNTech SE traces its origins to the research laboratories of the University of Mainz in the early 2000s, where Ugur Sahin, a Turkish-born physician and immunologist, and Ozlem Tureci, a German physician with Turkish roots, were investigating why cancer immunotherapies failed so frequently in clinical practice. During this period, he and Tureci began adapting multiple technologies for therapeutic use, including antibodies, cell therapies, and mRNA.
The founders were supported by early investors including Dr. Thomas and Dr. Andreas Strüngmann, Michael Motschmann, and Helmut Jeggle, who provided the capital to transform academic research into a commercial enterprise. The founding team brought complementary expertise: Sahin as CEO and scientific visionary, Tureci as Chief Medical Officer and clinical strategist, and Huber as a scientific co-founder. On January 25, 2020 — weeks before the World Health Organization declared a pandemic — Sahin launched "Project Lightspeed," directing BioNTech's resources toward developing an mRNA vaccine against SARS-CoV-2. The project used two decades of mRNA platform development that had originally been intended for cancer immunotherapy.
Yet the founders consistently emphasized that economic success was secondary to their scientific mission. Throughout the pandemic, they maintained focus on the original vision of cancer immunotherapy, using COVID vaccine profits to fund oncology pipeline expansion.
Prof. Ugur Sahin, M.D. is the Co-Founder, Chief Executive Officer, and Chair of the Management Board of BioNTech SE. Born in Turkey and raised in Germany, Sahin trained as a physician and immunologist, completing his medical doctorate at the University of Cologne with a focus on cancer immunotherapy. He held academic positions at Saarland University Medical Center, the University of Zurich, and the University of Mainz, where he established a research group in 2000 and became a professor of experimental oncology in 2006. In 2001, he co-founded Ganymed Pharmaceuticals with Ozlem Tureci and Christoph Huber, developing zolbetuximab for gastric and esophageal cancers. Ganymed was acquired by Astellas Pharma in 2016 for over $436 million after demonstrating significant overall survival benefit in a randomized clinical trial. Sahin launched BioNTech in 2008 to pursue individualized cancer immunotherapies based on mRNA technology, and in January 2020—weeks before the WHO pandemic declaration—he initiated 'Project Lightspeed' to develop an mRNA vaccine against SARS-CoV-2, leveraging two decades of platform development. Under his leadership, BioNTech developed the world's first approved mRNA medicine (Comirnaty) and is now pivoting the company toward oncology with over 20 active late-stage clinical trials. Sahin holds a minority interest in the listed company and has consistently emphasized that economic success is secondary to the scientific mission of improving patient outcomes. He is married to co-founder Ozlem Tureci.
Prof. Ozlem Tureci, M.D. is the Co-Founder, Chief Medical Officer, and Member of the Management Board of BioNTech SE. A German physician and immunologist with Turkish roots, Tureci trained at Saarland University Medical Center where she met and later married Ugur Sahin in 2002. Her clinical practice in oncology provided the foundational insight for BioNTech's mission: that the genetic heterogeneity of tumors—less than 3% similarity between patients with the same cancer type—was the root cause of treatment failure for standardized therapies. Tureci co-founded BioNTech in 2008 to develop individualized immunotherapies that could address this heterogeneity, initially focusing on mRNA-based cancer vaccines. She has led the clinical development strategy for all BioNTech programs, from the early cancer vaccine trials through the COVID-19 vaccine development and now the oncology pipeline pivot. As Chief Medical Officer, she oversees clinical trial design, regulatory strategy, and medical affairs. Tureci has been instrumental in establishing BioNTech's partnerships with Genentech/Roche, Pfizer, and other global pharmaceutical companies. She has received numerous honors including the German Future Prize (Deutscher Zukunftspreis) in 2021 alongside Sahin for the COVID-19 vaccine development. Tureci's public statements consistently emphasize the goal of translating research into survival for patients worldwide.
Dr. Christoph Huber is a scientific co-founder of BioNTech SE and was previously a co-founder of Ganymed Pharmaceuticals alongside Ugur Sahin and Ozlem Tureci in 2001. At Ganymed, Huber contributed to the development of zolbetuximab, a monoclonal antibody targeting CLDN18.2 for gastric and esophageal cancers, which demonstrated significant overall survival benefit in randomized trials and led to the company's acquisition by Astellas Pharma in 2016 for over $436 million. Huber's expertise in antibody development and translational oncology research informed BioNTech's early technology platform decisions, including the initial focus on multiple therapeutic modalities beyond mRNA. While maintaining a lower public profile than Sahin and Tureci, Huber's scientific contributions were instrumental in establishing the research culture and technical capabilities that enabled BioNTech's later success.
Prof. Ugur Sahin, Prof. Ozlem Tureci, and Dr. Christoph Huber founded BioNTech SE in Mainz, Germany, with initial backing from investors including the Strüngmann brothers, Michael Motschmann, and Helmut Jeggle. The company was established to develop individualized cancer immunotherapies based on mRNA technology, following two decades of academic research at the University of Mainz and Saarland University Medical Center.
Katalin Karikó, the biochemist whose pioneering work on nucleoside-modified mRNA would prove foundational to COVID-19 vaccine development, joined BioNTech as Senior Vice President. Her research on modifying uridine in mRNA to reduce immunogenicity while maintaining translational efficiency was critical to making mRNA therapeutics clinically viable.
BioNTech completed its initial public offering on the Nasdaq Global Select Market under ticker symbol BNTX, raising capital as an emerging growth company and foreign private issuer. The IPO provided funding to advance the oncology pipeline and expand manufacturing capabilities, valuing the company at approximately $3.4 billion at pricing.
On January 25, 2020, Ugur Sahin launched 'Project Lightspeed' to develop an mRNA vaccine against SARS-CoV-2, weeks before the WHO pandemic declaration. In March 2020, BioNTech announced its collaboration with Pfizer Inc. to jointly develop, manufacture, and commercialize the COVID-19 vaccine, with Pfizer providing global infrastructure and BioNTech contributing the mRNA platform.
On December 2, 2020, the Pfizer-BioNTech BNT162b2 vaccine received emergency use authorization from the UK Medicines and Healthcare products Regulatory Agency, becoming the world's first approved mRNA-based medicine and the first COVID-19 vaccine authorized for widespread use. FDA authorization followed on December 11, 2020.
For the fiscal year ended December 31, 2021, BioNTech reported total revenues of $20,684.6 million ($22.0 billion), with net profit of $11,218.8 million and diluted earnings per share of $43.20 ($46.87). The company delivered approximately 2.6 billion doses of Comirnaty to more than 165 countries and regions, including over 1 billion doses to low- and middle-income countries.
Total revenues declined to $18,868.6 million in 2022 as COVID-19 vaccine demand began normalizing, though the company still generated $15,643.8 million in gross profit share from the Pfizer collaboration. BioNTech began explicitly reinvesting pandemic profits into oncology pipeline expansion, increasing R&D expenses and headcount.
Total revenues fell to $4,162.7 million in 2023, a 78% decline from 2022, as COVID-19 vaccine demand collapsed and the virus entered endemic stages. The company maintained profitability with net profit of $1,014.0 million but began accelerating oncology investments, with non-COVID R&D expenses increasing to $1.60 billion.
For fiscal year 2024, BioNTech reported revenues of $2,998.7 million, a net loss of $725.2 million, and diluted loss per share of $3.02 ($3.00). R&D expenses surged 26% to $2.45 billion, with over 20 active Phase 2 and 3 oncology trials. The company maintained $19.0 billion in cash and securities while guiding 2025 revenues to $1.9-2.2 billion.
In November 2024, BioNTech signed an agreement to acquire Biotheus for $800 million upfront plus up to $150 million in milestones, securing full global rights to BNT327 (PM8002), a bispecific antibody targeting PD-L1 and VEGF-A. The acquisition, completed in February 2025, added a Chinese R&D hub with over 300 employees and an advanced biologics manufacturing facility.
In August 2025, BioNTech reached agreements with CureVac and GSK to resolve pending patent litigation regarding mRNA technology, agreeing to pay $370 million to GSK plus a 1% royalty on U.S. sales of mRNA COVID-19 and influenza products, with an additional $130 million and 1% rest-of-world royalty contingent on closing the CureVac acquisition.
BioNTech acquired Biotheus to secure full global rights to BNT327 (PM8002), a novel bispecific antibody combining PD-L1 checkpoint inhibition with VEGF-A neutralization. The acquisition also added an in-house antibody generation platform, bispecific ADC capabilities, and a Chinese R&D hub with over 300 employees and an advanced biologics manufacturing facility.
BioNTech acquired Gilead subsidiary Kite Pharma's cell therapy manufacturing facility in Marburg, Germany, to expand mRNA vaccine production capacity for the COVID-19 vaccine program. The facility was rapidly converted to GMP mRNA manufacturing.
BioNTech acquired InstaDeep, a Tunisian-British AI company specializing in deep learning and computational biology, to enhance its neoantigen prediction capabilities and drug discovery platform.
BioNTech, founded in 2008 in Mainz, Germany by husband-wife team Uğur Şahin and Özlem Türeci with twin brothers Christoph and Andreas Strüngmann's investment, spent 12 years developing mRNA cancer vaccine technology before COVID-19 created an unprecedented opportunity. When Şahin recognised in January 2020 that the SARS-CoV-2 sequence published online was an mRNA-translatable target, BioNTech designed vaccine candidates within weeks, partnered with Pfizer in March 2020, and delivered the first authorised COVID-19 vaccine by December 2020 — under a year from concept to approval, compared to typical 10-15 year vaccine development. Comirnaty (BNT162b2) generated $60+ billion in cumulative Pfizer-BioNTech revenue, validated mRNA technology globally, and transformed BioNTech from a private cancer biotech into a public company with $20+ billion market cap.
Twin brothers Andreas and Thomas Strüngmann, who had sold their generic pharmaceutical company Hexal to Novartis for €5.65 billion in 2005, invested €150 million in BioNTech's 2008 founding and continued providing capital through 12 years of pre-revenue research — funding that BioNTech could not have raised from traditional venture capital given the long timeline. The Strüngmanns' patient capital allowed Şahin and Türeci to develop mRNA technology platforms for cancer immunotherapy without commercial pressure, building the infrastructure that enabled COVID-19 vaccine development. The brothers retained majority ownership through BioNTech's 2019 Nasdaq IPO and the subsequent COVID surge, with their stake reaching $20+ billion in 2021 — making them among Germany's wealthiest individuals while validating their thesis that German biotech could compete with US firms if given patient capital.
BioNTech's March 2020 partnership with Pfizer to co-develop the COVID-19 vaccine combined BioNTech's mRNA technology with Pfizer's vaccine manufacturing scale and global distribution, creating the partnership that delivered 4+ billion vaccine doses globally. The 50/50 profit-sharing structure (after deducting Pfizer's costs) generated $19 billion for BioNTech in 2021 alone — more than the company's entire prior fundraising — and provided the capital base for subsequent oncology investment. Without Pfizer, BioNTech could not have manufactured at scale (lacking the $2+ billion in facilities Pfizer brought) or navigated global regulatory approvals, demonstrating that strategic partnerships can be equally important as proprietary technology for breakthrough commercial success.
BioNTech's COVID vaccine revenue collapsed from $19 billion (2021) to $3.0 billion (2024) as global vaccination rates plateaued, forcing the company to pivot back to its original cancer immunotherapy focus that had been its 2008 founding mission. CEO Şahin announced plans to launch first mRNA cancer vaccines by 2026-2030, leveraging the COVID-era cash to fund 19+ oncology clinical programmes including individualised mRNA cancer vaccines, CAR-T cell therapies, and bispecific antibodies. The transition is challenging — oncology drugs require longer development timelines and higher clinical evidence standards than infectious disease vaccines — and BioNTech burns approximately $2 billion annually with no significant oncology revenue yet, requiring continued cash discipline as the COVID windfall sustains operations through the multi-year oncology pipeline maturation.
BioNTech was incorporated in Mainz, Germany on 2 June 2008 by Uğur Şahin, Özlem Türeci and Christoph Huber, who pooled three earlier research vehicles to create a single platform company focused on individualised cancer immunotherapy. The first was Ganymed Pharmaceuticals, founded by Şahin and Türeci in 2001 to develop monoclonal antibodies against cancer-specific surface antigens, later sold to Astellas Pharma in 2016 for up to €1.28 billion. The second was Ribological GmbH, a 2007 spinout from Johannes Gutenberg University Mainz that owned the foundational mRNA chemistry patents Şahin had filed for in vitro transcribed messenger RNA designed to express tumour antigens. The third was the TRON translational oncology institute, a non-profit centre Şahin co-founded that supplied early sequencing and bioinformatics infrastructure. The Strüngmann brothers, Thomas and Andreas, anchored the seed round with €150 million through MIG Fonds and AT Impf, taking what would become a roughly 50% stake. By 2013 BioNTech had attracted Genentech as its first major partner with a $310 million collaboration on individualised neoantigen vaccines, and by 2018 it had signed parallel deals with Sanofi, Bayer Animal Health and Pfizer, the last of which would prove decisive when COVID-19 emerged in Wuhan in December 2019.